JP2023534959A5 - - Google Patents

Info

Publication number
JP2023534959A5
JP2023534959A5 JP2023502897A JP2023502897A JP2023534959A5 JP 2023534959 A5 JP2023534959 A5 JP 2023534959A5 JP 2023502897 A JP2023502897 A JP 2023502897A JP 2023502897 A JP2023502897 A JP 2023502897A JP 2023534959 A5 JP2023534959 A5 JP 2023534959A5
Authority
JP
Japan
Prior art keywords
antibody
cancer cells
seq
fragment
muc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023502897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534959A (ja
JP7888216B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/070881 external-priority patent/WO2022016190A1/en
Publication of JP2023534959A publication Critical patent/JP2023534959A/ja
Publication of JP2023534959A5 publication Critical patent/JP2023534959A5/ja
Application granted granted Critical
Publication of JP7888216B2 publication Critical patent/JP7888216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023502897A 2020-07-16 2021-07-15 Muc1-c/細胞外ドメイン(muc1-c/ecd)に対する抗体 Active JP7888216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052599P 2020-07-16 2020-07-16
US63/052,599 2020-07-16
PCT/US2021/070881 WO2022016190A1 (en) 2020-07-16 2021-07-15 Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Publications (3)

Publication Number Publication Date
JP2023534959A JP2023534959A (ja) 2023-08-15
JP2023534959A5 true JP2023534959A5 (cg-RX-API-DMAC7.html) 2024-06-07
JP7888216B2 JP7888216B2 (ja) 2026-07-13

Family

ID=79554266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502897A Active JP7888216B2 (ja) 2020-07-16 2021-07-15 Muc1-c/細胞外ドメイン(muc1-c/ecd)に対する抗体

Country Status (11)

Country Link
US (1) US20230265208A1 (cg-RX-API-DMAC7.html)
EP (1) EP4182354A4 (cg-RX-API-DMAC7.html)
JP (1) JP7888216B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230116767A (cg-RX-API-DMAC7.html)
CN (1) CN117693530A (cg-RX-API-DMAC7.html)
AU (1) AU2021310499A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000728A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186181A1 (cg-RX-API-DMAC7.html)
IL (1) IL299903A (cg-RX-API-DMAC7.html)
MX (1) MX2023000784A (cg-RX-API-DMAC7.html)
WO (1) WO2022016190A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4676975A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Muc1 and cd16a antibodies and methods of use
TW202436357A (zh) * 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1抗體及使用方法
WO2025217515A2 (en) 2024-04-12 2025-10-16 Dana-Farber Cancer Institute, Inc. Identification of muc1-c as a target for the treatment of squamous cell carcinomas
KR20260100547A (ko) * 2024-12-20 2026-06-30 주식회사 펩트론 항-muc1 항체를 포함하는 면역 항암 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601417C (en) * 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
JP2012504961A (ja) * 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Muc1*抗体
CN106132992B (zh) * 2014-01-29 2020-08-07 达娜-法勃肿瘤研究所公司 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
US10617773B2 (en) * 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)

Similar Documents

Publication Publication Date Title
EP3237006B1 (en) Bispecific tetravalent antibodies and methods of making and using thereof
EP4286410A1 (en) Single-domain antibody against cd16a and use thereof
JP7438958B2 (ja) 新規な抗体分子、その調製方法及びその使用
US10781256B2 (en) Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies
JP6392923B2 (ja) Muc1*抗体
EP3397645B1 (en) Variable regions for nkp46 binding proteins
WO2018147245A1 (ja) 抗gprc5d抗体及び該抗体を含む分子
JP7851303B2 (ja) ヒトcd3イプシロンに結合する新規なヒト抗体
JP2023539501A5 (cg-RX-API-DMAC7.html)
IL302278A (en) Combination treatment
JP2023541473A (ja) 抗4-1bb-抗pd-l1二重特異性抗体、ならびにその医薬組成物および使用
US20240002544A1 (en) Cd28 bispecific antibodies for targeted t cell activation
CN113004408B (zh) 抗人程序死亡因子-1单克隆抗体
CN112830969B (zh) 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒
CN111655733A (zh) 共价多特异性抗体
CN103025760A (zh) 人源化egfr抗体
EP4155318A1 (en) Bispecific antibody and use thereof
WO2018176992A1 (zh) 新型双特异性抗体及其用途
JP2025520678A (ja) Ror1/egfr二重特異性抗原結合分子
CN114829405A (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
JP2022525393A (ja) 抗メソテリン抗体、抗cd3抗体又は抗egfr抗体を含む融合タンパク質、それを含む二重特異性又は三重特異性抗体、及びその使用
JP2024522116A5 (cg-RX-API-DMAC7.html)
CN120271715A (zh) 抗体及其药物偶联物和用途
WO2024235317A1 (zh) 结合lilrb4和cd3的抗体及其用途
KR20250042908A (ko) 항-메소텔린 항체 및 이의 용도